Predicted protein targets (top 17)
| gene | UniProt | supporting neighbours | confidence | |
|---|---|---|---|---|
| ▸ | DGKA | P23743 | 1/20 | 0.69 |
| ▸ | PAM | P19021 | 2/20 | 0.62 |
| ▸ | TSHR | P16473 | 2/20 | 0.58 |
| ▸ | MAPT | P10636 | 1/20 | 0.58 |
| ▸ | LMNA | P02545 | 4/20 | 0.56 |
| ▸ | ALDH1A1 | P00352 | 2/20 | 0.56 |
| ▸ | DNM1 | Q05193 | 1/20 | 0.56 |
| ▸ | KDM4E | B2RXH2 | 1/20 | 0.55 |
| ▸ | DUSP3 | P51452 | 1/20 | 0.55 |
| ▸ | MEN1 | O00255 | 1/20 | 0.55 |
| ▸ | KMT2A | Q03164 | 1/20 | 0.55 |
| ▸ | PRKCA | P17252 | 1/20 | 0.51 |
| ▸ | PRKCE | Q02156 | 1/20 | 0.51 |
| ▸ | PRKCQ | Q04759 | 1/20 | 0.51 |
| ▸ | PRKCD | Q05655 | 1/20 | 0.51 |
| ▸ | CES2 | O00748 | 3/20 | 0.50 |
| ▸ | CES1 | P23141 | 3/20 | 0.50 |
Click a target to see other patent compounds predicted against it — the reverse direction, in place.
Similar compounds — the chemically nearest patent molecules
Nearest neighbours by Morgan-fingerprint cosine across the patent-compound collection, with each neighbour's top predicted target and the predicted targets it shares with this molecule.
| Compound | similarity | top predicted | shared targets | |
|---|---|---|---|---|
| SCHEMBL1782819 | 1.00 | DGKA (0.69) | DGKAPAMTSHRMAPTLMNA | |
| SCHEMBL29366771 | 1.00 | DGKA (0.69) | DGKAPAMTSHRMAPTLMNA | |
| SCHEMBL10901771 | 1.00 | DGKA (0.69) | DGKAPAMTSHRMAPTLMNA | |
| SCHEMBL2857061 | 1.00 | DGKA (0.69) | DGKAPAMTSHRMAPTLMNA | |
| SCHEMBL28699910 | 1.00 | DGKA (0.69) | DGKAPAMTSHRMAPTLMNA | |
| SCHEMBL355177 | 1.00 | DGKA (0.69) | DGKAPAMTSHRMAPTLMNA | |
| SCHEMBL6266491 | 1.00 | DGKA (0.69) | DGKAPAMTSHRMAPTLMNA | |
| SCHEMBL10414846 | 1.00 | DGKA (0.69) | DGKAPAMTSHRMAPTLMNA | |
| SCHEMBL353797 | 1.00 | DGKA (0.69) | DGKAPAMTSHRMAPTLMNA | |
| SCHEMBL356145 | 1.00 | DGKA (0.69) | DGKAPAMTSHRMAPTLMNA |
Similarity is cosine over the 2,048-bit Morgan fingerprint (≈ Tanimoto). Identical fingerprints score 1.00.
Patent provenance — the patents this molecule appears in, and who filed them
Claimed or disclosed in 36 patents — showing the first 20. claimed = in the patent's claims; disclosed = body only.
| Patent | Title | Assignee | Published | Priority | Filing | Country | Status |
|---|---|---|---|---|---|---|---|
| CN-122070276-A | Prodrugs of xanomeline, prodrugs of trospium chloride and methods of using the same | 人类生物科学股份有限公司 | 2026-05-19 | — | — | CN | disclosed |
| EP-4705289-A1 | PRODRUGS OF XANOMELINE, PRODRUGS OF TROSPIUM AND METHODS OF USE THEREOF | Terran Biosciences Inc. (US) | 2026-03-11 | — | — | EP | disclosed |
| US-12269818-B2 | Analogs of xanomeline | TERRAN BIOSCIENCES INC. (US) | 2025-04-08 | — | — | US | disclosed |
| US-20240368149-A1 | ANALOGS OF XANOMELINE | TERRAN BIOSCIENCES INC. | 2024-11-07 | — | — | US | disclosed |
| WO-2024226691-A1 | PRODRUGS OF XANOMELINE, PRODRUGS OF TROSPIUM AND METHODS OF USE THEREOF | TERRAN BIOSCIENCES INC. (US) | 2024-10-31 | — | — | WO | disclosed |
| US-12030868-B2 | Prodrugs of CGRP antagonists | PFIZER IRELAND PHARMACEUTICALS (IE) | 2024-07-09 | — | — | US | disclosed |
| EP-4321164-A2 | COMPOUNDS WITH HIV MATURATION INHIBITORY ACTIVITY | ViiV Healthcare UK (No.5) Limited (GB) | 2024-02-14 | — | — | EP | disclosed |
| EP-3784349-B1 | COMPOUNDS WITH HIV MATURATION INHIBITORY ACTIVITY | VIIV HEALTHCARE UK NO 5 LTD (GB) | 2023-12-27 | — | — | EP | disclosed |
| WO-2023196614-A1 | METHODS AND COMPOUNDS FOR TREATING NEUROLOGICAL DISORDERS | AXONIS THERAPEUTICS, INC. (US) | 2023-10-12 | — | — | WO | disclosed |
| US-20230192758-A1 | COMPOUNDS WITH HIV MATURATION INHIBITORY ACTIVITY | VIIV Healthcare UK (No.5) Limited (GB) | 2023-06-22 | — | — | US | disclosed |
| US-20080119536-A1 | SUBSTITUTED IMIDAZOLES | PFIZER LIMITED (GB) | 2008-05-22 | — | — | US | disclosed |
| US-20070167506-A1 | SUBSTITUTED IMIDAZOLES | PFIZER INC. (US) | 2007-07-19 | — | — | US | disclosed |
| WO-2001056358-A2 | ENHANCED PROPERTIED PESTICIDES | ROHM AND HAAS COMPANY (US) | 2001-08-09 | — | — | WO | disclosed |
| US-5650172-A | Pharmaceutical preparation comprising fat emulsion of fat microparticles | TANABE SEIYAKU CO., LTD. (JP) | 1997-07-22 | — | — | US | disclosed |
| EP-0599543-B1 | Pharmaceutical preparation comprising fat emulsion of fat microparticles | TANABE SEIYAKU CO (JP) | 1996-10-02 | — | — | EP | disclosed |
| EP-0599543-A1 | Pharmaceutical preparation comprising fat emulsion of fat microparticles | TANABE SEIYAKU CO., LTD. (JP) | 1994-06-01 | — | — | EP | disclosed |
| EP-0588317-A1 | Uridine derivative and process for preparing the same | TANABE SEIYAKU CO., LTD. (JP) | 1994-03-23 | — | — | EP | disclosed |
| EP-0147177-B1 | ETHER PRODRUGS OF ANTI-INFLAMMATORY OXICAMS | PFIZER INC. (US) | 1987-10-14 | — | — | EP | disclosed |
| US-4551452-A | Anti-inflammatory 2-methyl-2H-1,2-benzo-(or -thieno-)thiazine-3-carboxamide 1,1-dioxide derivatives, compositions, and method of use therefor | PFIZER INC. (US) | 1985-11-05 | — | — | US | disclosed |
| EP-0147177-A2 | Ether prodrugs of anti-inflammatory oxicams | PFIZER INC. (US) | 1985-07-03 | — | — | EP | disclosed |
Patent text — is the patent's own abstract consistent with the prediction?
For each of this compound's patents that has machine-readable text (6 of them — usually the abstract, not the full specification), we ask MedCPT which protein the text reads most about, and where the chemistry-predicted target lands among 4885 human targets. A high rank means the patent's own wording is consistent with the prediction — a weak, independent signal, not proof of activity.
| Patent | Title | Text reads most about | Predicted target · text-rank |
|---|---|---|---|
| US-12030868-B2 | Prodrugs of CGRP antagonists | CALCRL, CALCA, CALCB | DGKA 2674/4885PAM 305/4885TSHR 1421/4885 |
| US-20230192758-A1 | COMPOUNDS WITH HIV MATURATION INHIBITORY ACTIVITY | OGFRL1, ZC3HAV1L, CD4 | DGKA 4594/4885PAM 3872/4885TSHR 4232/4885 |
| US-20240368149-A1 | ANALOGS OF XANOMELINE | HTR5A, HTR3A, HTR3B | DGKA 2991/4885PAM 1063/4885TSHR 399/4885 |
| US-12269818-B2 | Analogs of xanomeline | HTR5A, HTR3A, HTR3B | DGKA 2991/4885PAM 1063/4885TSHR 399/4885 |
| US-20070167506-A1 | SUBSTITUTED IMIDAZOLES | ABL1, TYR, CYP3A4 | DGKA 4575/4885PAM 1184/4885TSHR 3443/4885 |
| US-20080119536-A1 | SUBSTITUTED IMIDAZOLES | ABL1, TYR, CYP3A4 | DGKA 4575/4885PAM 1184/4885TSHR 3443/4885 |
“Text reads most about” is the patent abstract's nearest protein in MedCPT space (background-debiased). Only ~1.4% of patents have machine-readable text, so most compounds won't have this panel.